The latest price hike of the generic antibiotic nitrofurantoin isn’t doing any public relations favors for the already withering antibiotic industry.
The global backlash of Nostrum Pharmaceuticals’ 400 percent price spike adds fuel to the raging drug-price debate in the U.S. in which most politicians and patients argue drug prices are too high. Drug companies get even more flak for price hikes for drugs they didn’t develop, which is the case for Nostrum’s nitrofurantoin.
While the sticker price of Nostrum’s generic antibiotic has risen substantially, the antibiotic industry overall has seen waning profit margins for years. Over the past ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.